21 completed, 16 recruiting, 12 unknown, 9 not yet recruiting. 42 Phase 2, 22 Phase 1, 20 Phase 3, 2 Not applicable, 2 Phase 4.
Follow mFOLFOX6: new trials by email Literature Review of mFOLFOX6 trials Research Report on mFOLFOX6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma GDC-7035, Panitumumab, mFOLFOX6 - Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Genentech, Inc. | 388 | 2026-11-30 | 2026-11-10 |
| Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers Zolbetuximab, mFOLFOX6, CAPOX - Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | Midhun Malla | 32 | 2026-11-01 | 2026-11-02 |
| mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer cmFOLFOXIRI plus PD-1 inhibitor, mFOLFOX6 - Colon Cancer (Stage II &Amp;Amp; III) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 138 | 2026-10-01 | 2026-05-22 |
| EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer EMB-01, Irinotecan, TAS-102 - Unresectable/Metastatic Colorectal Cancer | Phase 1 | Recruiting | Shanghai EpimAb Biotherapeutics Co., Ltd. | 120 | 2026-09-30 | 2026-10-16 |
| NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 100 | 2026-09-01 | 2026-08-14 |
| Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer mFOLFOX6, Suvemcitug, Enlonstobart - Rectal Cancer | Phase 2 | Not yet recruiting | Fudan University | 52 | 2026-08-28 | 2026-09-09 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) Petosemtamab, Cetuximab, FOLFIRI - Left-sided Colorectal Cancer | Phase 3 | Recruiting | Genmab | 960 | 2026-08-11 | 2026-11-03 |
| A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer Cetuximab, mFOLFOX6 - mCRC | Phase 1 | Not yet recruiting | Shanghai Henlius Biotech | 387 | 2026-06-30 | 2026-04-24 |
| SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 3 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 204 | 2026-05-20 | 2026-07-01 |
| A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab - KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Recruiting | Kestrel Therapeutics, Inc. | 545 | 2026-04-21 | 2026-11-12 |
| Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study) mFOLFOX6, Serplulimab - Rectal Cancer | Phase 2 | Not yet recruiting | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 128 | 2026-02-01 | 2026-02-03 |
| Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2 - Stage I Colon Cancer, Stage II Colon Cancer | Phase 2 | Recruiting | Baylor College of Medicine | 28 | 2025-06-15 | 2025-05-25 |
| A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC) Cetuxima-β, Envafolimab, mFOLFOX6 - Metastatic Colorectal Cancer (CRC) | Phase 2 / Phase 3 | Not yet recruiting | Sun Yat-sen University | 590 | 2025-06-01 | 2025-05-06 |
| SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 49 | 2025-04-02 | 2026-08-04 |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin) - Non-Small Cell Lung Cancer, NSCLC | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 665 | 2025-03-31 | 2026-06-02 |
| A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations ALTA3263, cetuximab, mFOLFOX6 - Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Alterome Therapeutics, Inc. | 448 | 2025-03-05 | 2026-10-26 |
| Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients mFOLFIRINOX, mFolfox6 - Rectum Cancer | Phase 2 | Recruiting | Menoufia University | 100 | 2025-01-25 | 2025-02-19 |
| mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody, mFOLFOX6 - Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum | Phase 3 | Recruiting | Jun Huang | 166 | 2025-01-18 | 2025-12-24 |
| Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients cadonilimab, Trastuzumab, XELOX - Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Recruiting | Zhejiang Cancer Hospital | 90 | 2024-07-10 | 2024-10-21 |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine - Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Boehringer Ingelheim | 910 | 2024-06-28 | 2026-11-05 |
Showing 20 of 74. Sign in to see all of them.
Colorectal Neoplasms (35) · Rectal Neoplasms (16) · Colonic Neoplasms (9) · Neoplasm Metastasis (8) · Stomach Neoplasms (6) · Pancreatic Neoplasms (5) · Lung Neoplasms (3) · Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1)
Sun Yat-sen University (5) · Sixth Affiliated Hospital, Sun Yat-sen University (4) · Amgen (3) · Fudan University (3) · Five Prime Therapeutics, Inc. (2) · Genentech, Inc. (2) · Hoffmann-La Roche (2) · Ruijin Hospital (2) · Shanghai Henlius Biotech (2) · UNC Lineberger Comprehensive Cancer Center (2) · Xu jianmin (2) · Zhejiang University (2) · ASLAN Pharmaceuticals (1) · AVEO Pharmaceuticals, Inc. (1) · Aadi Bioscience, Inc. (1)
United States (31) · China (24) · France (8) · Spain (8) · Australia (7) · Belgium (7) · Italy (7) · Germany (6) · South Korea (6) · United Kingdom (6) · Canada (4) · Hungary (4) · Japan (4) · Taiwan (4) · Israel (3)
Atif Iqbal, MD (1) · Autumn McRee, MD (1) · Baruch Brenner, Prof (1) · Charlie Qi, MD (1) · Ding Ke-Feng, PHD/MD (1) · Dominik Modest, Prof. Dr. (1) · Guohui Wan, PhD. (1) · Guy van Hazel, MD (1) · Jieer Ying, MD (1) · Juan Huang, PhD. (1)
PMID 38308771, PMID 23569301, PMID 24457377, PMID 25487708, PMID 26032776, PMID 26049686, PMID 26109878, PMID 26903575, PMID 28351831, PMID 28781171, PMID 30081865, PMID 31840815, PMID 32749938, PMID 32965540, PMID 33207247, PMID 33264544, PMID 33812497, PMID 34446053, PMID 35366831, PMID 35427471, PMID 36244398, PMID 36369901, PMID 36852723, PMID 37923987, PMID 38084840, PMID 38309722, PMID 40016550, PMID 40341124, PMID 41108088, PMID 41790032, PMID 42134324
2017 (2), 2014 (1), 2015 (1), 2016 (1), 2019 (1), 2023 (1)